A Phase IIa, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of DA-9805 in Subjects With Parkinson's Disease
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2018
At a glance
- Drugs DA 9805 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; First in man
- Sponsors Dong-A ST
- 23 Feb 2018 Status changed from not yet recruiting to recruiting.
- 10 Aug 2017 Planned initiation date changed from 1 Jul 2017 to 1 Sep 2017.
- 21 Jun 2017 New trial record